1. Ren, Fei, Zhang, Wei, Lu, Shuai, Ren, Hong, Guo, Yantong. 2019. NRSN2 promotes breast cancer metastasis by activating PI3K/AKT/mTOR and NF-κB signaling pathways. In Oncology letters, 19, 813-823. doi:10.3892/ol.2019.11152. https://pubmed.ncbi.nlm.nih.gov/31885716/
2. Yan, Zhaoyang, Xu, Tongxin, Lu, Juntao, Guo, Wei, Dong, Zhiming. 2022. E2F1-activated NRSN2 promotes esophageal squamous cell carcinoma progression through AKT/mTOR pathway. In Pathology, research and practice, 236, 153963. doi:10.1016/j.prp.2022.153963. https://pubmed.ncbi.nlm.nih.gov/35662041/
3. Ren, Shenghui, Chen, Manyu, Chen, Yu, Ding, Ke. . NRSN2 is a Prognostic Biomarker in Gastric Cancer and Facilitates the Growth and Migration of Gastric Cancer Cells. In Protein and peptide letters, 30, 427-438. doi:10.2174/0929866530666230314160234. https://pubmed.ncbi.nlm.nih.gov/36918782/
4. Ma, Hai-Qing, Liang, Xiao-Ting, Zhao, Jing-Jing, Pan, Ke, Xia, Jian-Chuan. . Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. In World journal of gastroenterology, 15, 4844-8. doi:. https://pubmed.ncbi.nlm.nih.gov/19824122/
5. Tang, Wenbin, Ren, Aimin, Xiao, Hongyang, Sun, Huizhen, Li, Bin. 2016. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 85, 248-255. doi:10.1016/j.biopha.2016.11.012. https://pubmed.ncbi.nlm.nih.gov/27908706/
智鼠故事 
